Halozyme Therapeutics - HALO Stock Forecast, Price & News

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price target on Halozyme Therapeutics from $48.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, May 26th. StockNews.com downgraded shares of Halozyme Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, May 11th. Finally, SVB Leerink assumed coverage on shares of Halozyme Therapeutics in a report on Monday, May 23rd. They issued an "outperform" rating and a $52.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $52.33.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded down $0.26 during trading on Thursday, reaching $43.84. The company had a trading volume of 33,893 shares, compared to its average volume of 1,068,981. The firm has a market capitalization of $6.05 billion, a PE ratio of 17.43, a price-to-earnings-growth ratio of 0.68 and a beta of 1.20. The firm's 50-day simple moving average is $46.86 and its 200 day simple moving average is $41.54. The company has a debt-to-equity ratio of 3.03, a quick ratio of 8.42 and a current ratio of 8.85. Halozyme Therapeutics has a 1-year low of $31.36 and a 1-year high of $52.98.

Halozyme Therapeutics (NASDAQ:HALO - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.06. The business had revenue of $152.37 million for the quarter, compared to the consensus estimate of $156.00 million. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 106.57%. The company's revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $0.63 earnings per share. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 2.06 earnings per share for the current fiscal year.